Altered Functions of Neutrophils in Two Chinese Patients With Severe Congenital Neutropenia Type 4 Caused by G6PC3 Mutations

Rongxin Dai, Ge Lv, Wenyan Li, Wenjing Tang, Junjie Chen, Qiao Liu, Yang Lü, Min Zhang, Zhirui Tian, Lina Zhou, Xin Yan, Yating Wang, Yuan Ding, Yunfei An, Zhiyong Zhang, Xuemei Tang, Xiaodong ZhaoFrontiers in Immunology 2021 · DOI

Abstract

G-CSF treatment is insufficient for patients with SCN4 patients, who remain at risk of infection. Where possible, regular G-CSF treatment, long-term prevention of infection, are the optimal methods for cure of SCN4 patients. It is important to monitor closely for signs of leukemia in SCN4 patients. Once leukemia occurs in SCN4 patients, hematopoietic stem cell transplantation is the most important choice of treatment.

Introduction

Severe Congenital Neutropenia (SCN) represents a group of rare primary immunodeficiencies characterized by a profound deficit in circulating neutrophils, the primary "first responders" of the innate immune system. Type 4 (SCN4) is specifically linked to mutations in the G6PC3 gene, which encodes glucose-6-phosphatase catalytic subunit 3. This enzyme is vital for glucose metabolism within the endoplasmic reticulum (ER).

While Granulocyte Colony-Stimulating Factor (G-CSF) is the standard clinical intervention to stimulate neutrophil production, its efficacy is often limited to quantitative restoration. Patients frequently continue to suffer from recurrent infections and face a significant risk of malignant transformation into leukemia. This study investigates the "functional gap" in two Chinese pediatric patients, exploring why neutrophils fail to provide adequate immunity even when their counts are normalized by therapy.

Methods

Researchers performed a comprehensive analysis of two unrelated Chinese pediatric patients presenting with SCN4. The methodology integrated genetic, cellular, and immunological assays:

  • Genetic Analysis: Targeted deep sequencing and Sanger sequencing identified specific G6PC3 mutations.
  • Functional Assays: Neutrophil "weaponry" was evaluated via DHR flow cytometry to measure the respiratory burst (reactive oxygen species production) and Sytox Green plate assays to visualize Neutrophil Extracellular Traps (NETs).
  • Apoptosis and Survival: Annexin V and Propidium Iodide (PI) staining tracked the rate of programmed cell death.
  • Immune Repertoire: TREC and KREC (T-cell and B-cell receptor excision circles) levels were measured to assess the broader impact on the adaptive immune system.

Results

The study identified heterozygous G6PC3 mutations in both patients, including a novel missense mutation (c.596A>G) in Patient 2. While G-CSF treatment successfully increased the Absolute Neutrophil Count (ANC) in both patients, the functional quality of these cells remained severely compromised.

Clinical and cellular profile of SCN4 patients before and after G-CSF treatment.

Key findings included:

  • Respiratory Burst Deficiency: The Stimulation Index (SI) for respiratory burst was drastically reduced (12-13 in patients vs. 105 in healthy controls), indicating a near-total loss of chemical killing capacity.
  • Impaired NET Formation: Neutrophils from both patients failed to generate extracellular traps effectively, even under chemical stimulation.
  • Accelerated Apoptosis: Patient neutrophils exhibited significantly higher rates of spontaneous and FAS-induced death compared to controls, with live cell percentages hovering around 51-67% compared to 86% in healthy individuals.
  • Myelokathexis: Increased expression of the CXCR4 receptor suggested that mature neutrophils were being inappropriately retained in the bone marrow.

Discussion

The findings underscore a "Broken Soldier" phenomenon in SCN4: G-CSF provides a quantitative fix for a qualitative defect. The metabolic stress induced by G6PC3 deficiency leads to chronic ER stress, making neutrophils hypersensitive to apoptosis and functionally incompetent. Furthermore, the low TREC/KREC levels suggest that the bone marrow environment in SCN4 also impairs the development of T and B cells, indicating a more systemic immune failure than previously recognized.

Limitations and Future Directions

The study's primary limitation is its small sample size (n=2), typical for ultra-rare diseases. Future work must bridge the "black box" between chronic cellular stress and leukemic transformation. Potential therapeutic avenues include gene therapy via lentiviral correction of G6PC3 in hematopoietic stem cells, which could offer a more robust and permanent solution than G-CSF.

Conclusion

For SCN4 patients, quantity does not equal quality. While G-CSF can stabilize neutrophil counts, it does not restore their pathogen-killing functions or longevity. Clinical management must prioritize long-term infection prophylaxis and vigilant monitoring for leukemia, as standard therapy provides only a partial solution to this complex metabolic and immunological disorder.

Summary updated

Abstract

G-CSF treatment is insufficient for patients with SCN4 patients, who remain at risk of infection. Where possible, regular G-CSF treatment, long-term prevention of infection, are the optimal methods for cure of SCN4 patients. It is important to monitor closely for signs of leukemia in SCN4 patients. Once leukemia occurs in SCN4 patients, hematopoietic stem cell transplantation is the most important choice of treatment.
BibTeX
@inproceedings{dai2021altered,
  author = {Rongxin Dai and Ge Lv and Wenyan Li and Wenjing Tang and Junjie Chen and Qiao Liu and Yang Lü and Min Zhang and Zhirui Tian and Lina Zhou and Xin Yan and Yating Wang and Yuan Ding and Yunfei An and Zhiyong Zhang and Xuemei Tang and Xiaodong Zhao},
  title = {{Altered Functions of Neutrophils in Two Chinese Patients With Severe Congenital Neutropenia Type 4 Caused by G6PC3 Mutations}},
  booktitle = {Frontiers in Immunology},
  year = {2021},
  doi = {10.3389/fimmu.2021.699743},
}
Figure